welcomes you to the new, improved website!Short- and mid-term outcomes of TAVR for nonagenarian (>90 years) patients in the PARTNER-1 trial were assessed for 531 pts. MACE occurred in 35% including stroke in 3.6%. Important paravalvular leak occurred in 1.4%. 30-day mortality was 4% and 3-year mortality was 48%, which compared to 44% in a matched population. QOL stabilized at 6 months and was better than preop. A trans-apical approach had a higher risk of 30-day and 3-year mortality.
You are here:
Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial
Submitted by: Mark Ferguson
Source: Annals of Thoracic Surgery
Keywords:
Author(s): Vinod H. Thourani, Hanna A. Jensen, Vasilis Babaliaros, Susheel K. Kodali, Jeevanantham Rajeswaran, John Ehrlinger, Eugene H. Blackstone, Rakesh M. Suri, Creighton W. Don, Gabriel Aldea, Mathew R. Williams, Raj Makkar, Lars G. Svensson, James M. McCabe, Larry S. Dean, Samir Kapadia, David J. Cohen, Augusto D. Pichard, Wilson Y. Szeto, Howard C. Herrmann, Chandan Devireddy, Bradley G. Leshnower, Gorav Ailawadi, Hersh S. Maniar, Rebecca T. Hahn, Martin B. Leon, Michael Mack.
